End-stage liver disease in persons with hemophilia and transfusion-associated infections

James J. Goedert, M. Elaine Eyster, Michael M. Lederman, Titica Mandalaki, Philippe De Moerloose, Gilbert C. White, Anne L. Angiolillo, Naomi L.C. Luban, Kenneth E. Sherman, Marilyn Manco-Johnson, Liliana Preiss, Cindy Leissinger, Craig M. Kessler, Alan R. Cohen, Donna Dimichele, Margaret W. Hilgartner, Louis M. Aledort, Barbara L. Kroner, Philip S. Rosenberg, Angelos Hatzakis

    Research output: Contribution to journalArticle

    152 Citations (Scopus)

    Abstract

    Many persons with hemophilia were infected with hepatitis C and B viruses (HCV, HBV) and HIV, but the consequences of these transfusion-acquired infections are poorly defined. We estimated the risk of HCV-related end-stage liver disease (ESLD) and the associations of age, HBV, and HIV with that risk. All 1816 HCV-seropositive hemophilic patients at 16 centers were followed for up to 16 years. Of these, 624 were HIV- and 1192 were HIV-coinfected; 135 had persistent HBV surface antigenemia, 1374 had resolved HBV infection, and 287 were HBV-uninfected. ESLD was defined as bleeding esophageal vaHces, hepatic ehcephalopathy, persistent ascites, or death excluding nonhepatic causes of these conditions. Competing risk models were used to estimate the annual hazard rate and cumulative incidence of ESLD. Proportional hazards models were used to estimate relative hazards of ESLD with covariates. ESLD developed in 127 of the HCV/HIV-coinfected participants, with an estimated 16-year cumulative incidence of 14.0% (95% confidence interval [CI], 11.6%-16.4%). Without HIV, 10 HCV-infected participants developed ESLD, for a significantly lower cumulative incidence of 2.6% (95% Cl, 1.0%-4.3%, P < .0001). ESLD risk increase steeply with age in both groups. With HIV, ESLD risk was increased 8.1-fold (95% Cl, 1.9-35.2) with HBV surface antigenemia, 2.1-fold (95% Cl, 1.3-3.3) with fewer than 0.2 × 109/L (200/μL) CD4+ lymphocytes, and 1.04-fold (95% Cl, 1.03-1.06) per year of age. Thus, HIV Is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4+ lymphocytes, or older age.

    Original languageEnglish (US)
    Pages (from-to)1584-1589
    Number of pages6
    JournalBlood
    Volume100
    Issue number5
    StatePublished - Sep 1 2002

    Fingerprint

    End Stage Liver Disease
    Hemophilia A
    Liver
    HIV
    Infection
    Hazards
    Lymphocytes
    Incidence
    Viruses
    Proportional Hazards Models
    Ascites
    Hepatitis B virus
    Hepacivirus
    Confidence Intervals
    Hemorrhage

    All Science Journal Classification (ASJC) codes

    • Biochemistry
    • Immunology
    • Hematology
    • Cell Biology

    Cite this

    Goedert, J. J., Eyster, M. E., Lederman, M. M., Mandalaki, T., De Moerloose, P., White, G. C., ... Hatzakis, A. (2002). End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood, 100(5), 1584-1589.
    Goedert, James J. ; Eyster, M. Elaine ; Lederman, Michael M. ; Mandalaki, Titica ; De Moerloose, Philippe ; White, Gilbert C. ; Angiolillo, Anne L. ; Luban, Naomi L.C. ; Sherman, Kenneth E. ; Manco-Johnson, Marilyn ; Preiss, Liliana ; Leissinger, Cindy ; Kessler, Craig M. ; Cohen, Alan R. ; Dimichele, Donna ; Hilgartner, Margaret W. ; Aledort, Louis M. ; Kroner, Barbara L. ; Rosenberg, Philip S. ; Hatzakis, Angelos. / End-stage liver disease in persons with hemophilia and transfusion-associated infections. In: Blood. 2002 ; Vol. 100, No. 5. pp. 1584-1589.
    @article{03aa6cf1e44244f2b5e0ed3beaf7eaf9,
    title = "End-stage liver disease in persons with hemophilia and transfusion-associated infections",
    abstract = "Many persons with hemophilia were infected with hepatitis C and B viruses (HCV, HBV) and HIV, but the consequences of these transfusion-acquired infections are poorly defined. We estimated the risk of HCV-related end-stage liver disease (ESLD) and the associations of age, HBV, and HIV with that risk. All 1816 HCV-seropositive hemophilic patients at 16 centers were followed for up to 16 years. Of these, 624 were HIV- and 1192 were HIV-coinfected; 135 had persistent HBV surface antigenemia, 1374 had resolved HBV infection, and 287 were HBV-uninfected. ESLD was defined as bleeding esophageal vaHces, hepatic ehcephalopathy, persistent ascites, or death excluding nonhepatic causes of these conditions. Competing risk models were used to estimate the annual hazard rate and cumulative incidence of ESLD. Proportional hazards models were used to estimate relative hazards of ESLD with covariates. ESLD developed in 127 of the HCV/HIV-coinfected participants, with an estimated 16-year cumulative incidence of 14.0{\%} (95{\%} confidence interval [CI], 11.6{\%}-16.4{\%}). Without HIV, 10 HCV-infected participants developed ESLD, for a significantly lower cumulative incidence of 2.6{\%} (95{\%} Cl, 1.0{\%}-4.3{\%}, P < .0001). ESLD risk increase steeply with age in both groups. With HIV, ESLD risk was increased 8.1-fold (95{\%} Cl, 1.9-35.2) with HBV surface antigenemia, 2.1-fold (95{\%} Cl, 1.3-3.3) with fewer than 0.2 × 109/L (200/μL) CD4+ lymphocytes, and 1.04-fold (95{\%} Cl, 1.03-1.06) per year of age. Thus, HIV Is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4+ lymphocytes, or older age.",
    author = "Goedert, {James J.} and Eyster, {M. Elaine} and Lederman, {Michael M.} and Titica Mandalaki and {De Moerloose}, Philippe and White, {Gilbert C.} and Angiolillo, {Anne L.} and Luban, {Naomi L.C.} and Sherman, {Kenneth E.} and Marilyn Manco-Johnson and Liliana Preiss and Cindy Leissinger and Kessler, {Craig M.} and Cohen, {Alan R.} and Donna Dimichele and Hilgartner, {Margaret W.} and Aledort, {Louis M.} and Kroner, {Barbara L.} and Rosenberg, {Philip S.} and Angelos Hatzakis",
    year = "2002",
    month = "9",
    day = "1",
    language = "English (US)",
    volume = "100",
    pages = "1584--1589",
    journal = "Blood",
    issn = "0006-4971",
    publisher = "American Society of Hematology",
    number = "5",

    }

    Goedert, JJ, Eyster, ME, Lederman, MM, Mandalaki, T, De Moerloose, P, White, GC, Angiolillo, AL, Luban, NLC, Sherman, KE, Manco-Johnson, M, Preiss, L, Leissinger, C, Kessler, CM, Cohen, AR, Dimichele, D, Hilgartner, MW, Aledort, LM, Kroner, BL, Rosenberg, PS & Hatzakis, A 2002, 'End-stage liver disease in persons with hemophilia and transfusion-associated infections', Blood, vol. 100, no. 5, pp. 1584-1589.

    End-stage liver disease in persons with hemophilia and transfusion-associated infections. / Goedert, James J.; Eyster, M. Elaine; Lederman, Michael M.; Mandalaki, Titica; De Moerloose, Philippe; White, Gilbert C.; Angiolillo, Anne L.; Luban, Naomi L.C.; Sherman, Kenneth E.; Manco-Johnson, Marilyn; Preiss, Liliana; Leissinger, Cindy; Kessler, Craig M.; Cohen, Alan R.; Dimichele, Donna; Hilgartner, Margaret W.; Aledort, Louis M.; Kroner, Barbara L.; Rosenberg, Philip S.; Hatzakis, Angelos.

    In: Blood, Vol. 100, No. 5, 01.09.2002, p. 1584-1589.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - End-stage liver disease in persons with hemophilia and transfusion-associated infections

    AU - Goedert, James J.

    AU - Eyster, M. Elaine

    AU - Lederman, Michael M.

    AU - Mandalaki, Titica

    AU - De Moerloose, Philippe

    AU - White, Gilbert C.

    AU - Angiolillo, Anne L.

    AU - Luban, Naomi L.C.

    AU - Sherman, Kenneth E.

    AU - Manco-Johnson, Marilyn

    AU - Preiss, Liliana

    AU - Leissinger, Cindy

    AU - Kessler, Craig M.

    AU - Cohen, Alan R.

    AU - Dimichele, Donna

    AU - Hilgartner, Margaret W.

    AU - Aledort, Louis M.

    AU - Kroner, Barbara L.

    AU - Rosenberg, Philip S.

    AU - Hatzakis, Angelos

    PY - 2002/9/1

    Y1 - 2002/9/1

    N2 - Many persons with hemophilia were infected with hepatitis C and B viruses (HCV, HBV) and HIV, but the consequences of these transfusion-acquired infections are poorly defined. We estimated the risk of HCV-related end-stage liver disease (ESLD) and the associations of age, HBV, and HIV with that risk. All 1816 HCV-seropositive hemophilic patients at 16 centers were followed for up to 16 years. Of these, 624 were HIV- and 1192 were HIV-coinfected; 135 had persistent HBV surface antigenemia, 1374 had resolved HBV infection, and 287 were HBV-uninfected. ESLD was defined as bleeding esophageal vaHces, hepatic ehcephalopathy, persistent ascites, or death excluding nonhepatic causes of these conditions. Competing risk models were used to estimate the annual hazard rate and cumulative incidence of ESLD. Proportional hazards models were used to estimate relative hazards of ESLD with covariates. ESLD developed in 127 of the HCV/HIV-coinfected participants, with an estimated 16-year cumulative incidence of 14.0% (95% confidence interval [CI], 11.6%-16.4%). Without HIV, 10 HCV-infected participants developed ESLD, for a significantly lower cumulative incidence of 2.6% (95% Cl, 1.0%-4.3%, P < .0001). ESLD risk increase steeply with age in both groups. With HIV, ESLD risk was increased 8.1-fold (95% Cl, 1.9-35.2) with HBV surface antigenemia, 2.1-fold (95% Cl, 1.3-3.3) with fewer than 0.2 × 109/L (200/μL) CD4+ lymphocytes, and 1.04-fold (95% Cl, 1.03-1.06) per year of age. Thus, HIV Is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4+ lymphocytes, or older age.

    AB - Many persons with hemophilia were infected with hepatitis C and B viruses (HCV, HBV) and HIV, but the consequences of these transfusion-acquired infections are poorly defined. We estimated the risk of HCV-related end-stage liver disease (ESLD) and the associations of age, HBV, and HIV with that risk. All 1816 HCV-seropositive hemophilic patients at 16 centers were followed for up to 16 years. Of these, 624 were HIV- and 1192 were HIV-coinfected; 135 had persistent HBV surface antigenemia, 1374 had resolved HBV infection, and 287 were HBV-uninfected. ESLD was defined as bleeding esophageal vaHces, hepatic ehcephalopathy, persistent ascites, or death excluding nonhepatic causes of these conditions. Competing risk models were used to estimate the annual hazard rate and cumulative incidence of ESLD. Proportional hazards models were used to estimate relative hazards of ESLD with covariates. ESLD developed in 127 of the HCV/HIV-coinfected participants, with an estimated 16-year cumulative incidence of 14.0% (95% confidence interval [CI], 11.6%-16.4%). Without HIV, 10 HCV-infected participants developed ESLD, for a significantly lower cumulative incidence of 2.6% (95% Cl, 1.0%-4.3%, P < .0001). ESLD risk increase steeply with age in both groups. With HIV, ESLD risk was increased 8.1-fold (95% Cl, 1.9-35.2) with HBV surface antigenemia, 2.1-fold (95% Cl, 1.3-3.3) with fewer than 0.2 × 109/L (200/μL) CD4+ lymphocytes, and 1.04-fold (95% Cl, 1.03-1.06) per year of age. Thus, HIV Is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4+ lymphocytes, or older age.

    UR - http://www.scopus.com/inward/record.url?scp=0036721470&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0036721470&partnerID=8YFLogxK

    M3 - Article

    C2 - 12176875

    AN - SCOPUS:0036721470

    VL - 100

    SP - 1584

    EP - 1589

    JO - Blood

    JF - Blood

    SN - 0006-4971

    IS - 5

    ER -

    Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002 Sep 1;100(5):1584-1589.